ImClone Systems Corporation
Overview
ImClone Systems wants to create identically successful cancer drug candidates. The company, a subsidiary of Eli Lilly, is focused on the development of oncology-related antibody therapies. The biotech research firm's only commercial product, Erbitux, is approved for treatment of colorectal cancer, as well as head and neck cancers. ImClone Systems co-promotes the drug with Bristol-Myers Squibb (BMS) in North America and with Merck KGaA elsewhere. The company is continuing to develop Erbitux as a possible treatment for other kinds of cancer, including lung cancer. It also has other potential oncology treatments in development.
Sample OverviewKey Numbers from Hoover's UK
Key financials for ImClone Systems Corporation
| Company Type | Subsidiary of Eli Lilly |
|---|---|
| Fiscal Year-End | December |
Key People from Hoover's UK
Key people and executives for ImClone Systems Corporation
| President | Bernhard Ehmer (Subscribers see complete biographies -- view sample)
|
|---|---|
| VP and CFO | Brian Batchelder |
| SVP Global and Development Operations | Andreas Harstrick |
Top Competitors from Hoover's UK
Top competitors of ImClone Systems Corporation
There are 17 competitors for ImClone; see more.
